The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum
Diabetologia · 2024-09 · 67 (9) · 1760-1782
DOI: 10.1007/s00125-024-06198-1 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetologia, online erschienen am 24.06.2024. Verfasst von Mariana Byndloss und 8 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University Medical Center, Nashville, TN, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 237 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, NIDDK NIH HHS, Novo Nordisk.
Themen: Diabetes mellitus
Abstract (Originalsprache)
This article summarises the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organised by Diabetes , Diabetes Care , and Diabetologia , which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: (1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g. genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomisation in humans; (2) the highly individualised nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; (3) because single time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and (4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Vanderbilt University Medical Center, Nashville, TN, USA.
- Howard Hughes Medical Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
- Cedars-Sinai Medical Center, Human Microbiome Research Institute, Los Angeles, CA, USA.
- University of Arizona, Tucson, AZ, USA.
- Department of Biomedicine, University of Basel, Basel, Switzerland.
- Department of Gastroenterology and Hepatology, University Digestive Healthcare Center, Clarunis, Basel, Switzerland.
Förderung
- NIEHS NIH HHS
- NIDDK NIH HHS
- Novo Nordisk
Zitieren
APA
Byndloss, M., Devkota, S., Duca, F., Niess, J. H., Nieuwdorp, M., Orho-Melander, M., Sanz, Y., Tremaroli, V., & Zhao, L. (2024). The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia, 67(9), 1760-1782. https://doi.org/10.1007/s00125-024-06198-1
Vancouver
Byndloss M, Devkota S, Duca F, Niess JH, Nieuwdorp M, Orho-Melander M, et al. The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetologia. 2024;67(9):1760-1782. doi:10.1007/s00125-024-06198-1
BibTeX
@article{Byndloss2024,
author = {Byndloss, Mariana and Devkota, Suzanne and Duca, Frank and Niess, Jan Hendrik and Nieuwdorp, Max and Orho-Melander, Marju and Sanz, Yolanda and Tremaroli, Valentina and Zhao, Liping},
title = {The gut microbiota and diabetes: research, translation, and clinical applications – 2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum},
journal = {Diabetologia},
year = {2024},
volume = {67},
number = {9},
pages = {1760--1782},
doi = {10.1007/s00125-024-06198-1}
}
EUVIMED